CA-RESMED/PROPELLER
7.1.2019 22:07:06 CET | Business Wire | Press release
ResMed (NYSE: RMD) (ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, today announced it has completed its acquisition of Propeller Health, a digital therapeutics company providing connected health solutions for people living with chronic obstructive pulmonary disease (COPD) and asthma.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190107005976/en/
Propeller will continue to operate as a standalone business out of its Madison, Wisc., and San Francisco offices, working with leading pharmaceutical partners and other healthcare organizations to provide digital therapeutics and actionable insights to people who use inhalers, helping improve their medication adherence, increase their number of symptom-free days, and reduce emergency room visits.
“I’m excited to welcome Propeller, a fellow digital health innovator and high-performing company, into the ResMed family,” said ResMed CEO Mick Farrell. “Propeller’s digital solutions and partnerships strengthen ResMed’s larger suite of products that can treat millions of people at various stages of their COPD and other chronic diseases, all aimed at improving people’s quality of life, while reducing the effects of these diseases, hospitalizations, and the overall cost of healthcare.”
Propeller will operate within ResMed’s Respiratory Care portfolio; Propeller CEO David Van Sickle remains in his role, reporting to ResMed Respiratory Care President Richie McHale.
As ResMed first reported on December 3, 2018, the addition of Propeller’s business is expected to have a dilutive impact on ResMed’s non-GAAP earnings per share in the range of $0.01 to $0.02 per quarter during the remainder of Fiscal Year 2019.
About ResMed
At ResMed (NYSE: RMD) (ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.
About Propeller Health
Propeller Health is a leading digital therapeutics company dedicated to the development and commercialization of measurably better medicines. Propeller creates products to more effectively treat chronic respiratory disease and improve clinical outcomes for patients through connectivity, analytics, and companion digital experiences. The Propeller platform is used by patients, physicians and healthcare organizations in the United States, Europe and Asia. For more information, visit www.propellerhealth.com .
Forward-looking statements
Statements contained in this news release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed's projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products and the integration of acquisitions – are subject to risks and uncertainties that could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed's periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190107005976/en/
Contact:
For media: Jayme Rubenstein +1 858.836.6798 news@resmed.com
For investors: Amy Wakeham +1 858.836.5000 investorrelations@resmed.com
Link:
Social Media:
https://www.facebook.com/PropellerHealth/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capcom’s Official Street Fighter 6 World Championship Tournaments Attract Record-high 20,000 Attendees16.3.2026 14:00:00 CET | Press release
– Capcom aims to accelerate growth of the global competitive scene with a larger total prize pool of over $2.1 million in the upcoming 2026 season – Capcom Co., Ltd. (TOKYO:9697) today announced that Capcom Cup 12 and Street Fighter League: World Championship 2025, its official world championship tournaments to determine the top Street Fighter 6 competitors, which were held at Ryogoku Kokugikan Arena from March 11-15, achieved a record-high of 20,000 attendees, concluding with great success. At Capcom Cup 12, which features matches against individual players, SAHARA (21 years old), who is a first‑year professional player, claimed the championship title in his debut appearance, while in the team-based competition Street Fighter League: World Championship 2025, Japanese representatives REJECT were the winning team. Capcom additionally announced that it will hold next season’s Capcom Cup 13 and Street Fighter League: World Championship 2026 at Ryogoku Kokugikan Arena. Furthermore, the com
Capcom’s Resident Evil Requiem Sales Exceed 6 Million Units!16.3.2026 14:00:00 CET | Press release
– Capcom also plans to release additional game content – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of Resident Evil Requiem, released on February 27, 2026, now exceed 6 million units, which is the fastest that a title in the series has reached this milestone. Resident Evil Requiem is the latest installment in the Resident Evil series, which offers photorealistic visuals and a deep sense of immersion. Players can enjoy the elevated essence of the survival horror experience by the interplay between intense fear and exhilarating action, made possible by two protagonists. Going forward, Capcom plans to implement several measures, such as ongoing support and additional game content, so players can continue to enjoy the title longer. In addition, the Resident Evil series will celebrate its 30th anniversary on March 22,2026. Capcom is readying various plans for this anniversary to delight series fans, such as a collaboration between Universal Studios Japan and Residen
Helical Fusion Announces Construction Site for Phase 1 of “Helix HARUKA,” Marking Transition to Manufacturing and Assembly of Fusion Hardware16.3.2026 14:00:00 CET | Press release
Advances one of Japan’s leading public-private partnership initiatives for fusion commercialization with NIFS and industrial partners Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; “Helical Fusion”), a Japanese fusion energy company advancing the Helix Program and developing the Helical Stellarator for commercial fusion power plants, announced the construction site for Phase 1 of Helix HARUKA, its Integrated Demonstration Device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316066384/en/ Concept image of Helix HARUKA, Helical Fusion’s integrated demonstration device Phase 1—the magnet demonstration phase—will be built in a dedicated workspace for the joint research group formed by Helical Fusion and the National Institute for Fusion Science (NIFS), located on the NIFS campus. Helical Fusion has already begun manufacturing phase and site build-out, with the aim of conducting coil current (ene
HyperLight Demonstrates Low-Power 1.6T-DR8 TFLN-based Reference Transceiver Assembled by TFC16.3.2026 13:03:00 CET | Press release
HyperLight Corporation (“HyperLight”) today announced a major milestone in low-power optical networking with the demonstration of a 1.6T-DR8 optical transceiver leveraging HyperLight’s TFLN Chiplet™ Platform. The reference module was demonstrated with engineering and manufacturing support from Suzhou TFC Optical Communication Co., Ltd. (SZSE: 300394, or "TFC"). The reference design achieves 20W power consumption in a fully retimed 1.6T-DR8 module, representing approximately 20% lower module-level power compared to alternative technologies. The reduction is achieved through a simple drop-in transmitter implementation based on a single thin-film lithium niobate photonic integrated circuit (TFLN PIC). The TFLN transmitter enables the module to operate using a single continuous-wave (CW) laser, compared to the two to four lasers typically required in conventional implementations. Additional energy savings are achieved through the ability to operate directly from the native low-swing electr
GCE® Launches Gascontrol.com Website Showcasing Its Complete Gas Control Portfolio for Speciality, Medical, and Industrial Applications16.3.2026 13:00:00 CET | Press release
GCE®, a global market leader for gas control equipment, has launched gascontrol.com, a new website designed to better serve customers across its GCE Specialty, GCE Medical, and GCE Industrial product portfolios. The new site provides a streamlined, market-focused experience that makes it easier for users to explore GCE’s gas control solutions and identify the right products. A new Documentation Search Tool assists customers in easily finding documents such as instructions for use (IFUs), appendices, and certifications through an intuitive search interface. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316410525/en/ GCE’s new website, gascontrol.com, provides a streamlined, market-focused experience across the GCE Specialty, GCE Medical, and GCE Industrial product portfolios. “The redesigned website reflects GCE’s role as a comprehensive, trusted supplier of gas control technologies that elevate industries and improve liv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom